First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

NCT05489237 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

278

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Neoplasms
Gastrointestinal Stromal Tumor (GIST)
Digestive System Disease
Gastrointestinal Diseases
Metastatic Cancer

Interventions

DRUG: IDRX-42

Sponsor

IDRX, Inc., a wholly owned subsidiary of GSK, LLC